Literature DB >> 8608491

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy.

R Heller1, M J Jaroszeski, L F Glass, J L Messina, D P Rapaport, R C DeConti, N A Fenske, R A Gilbert, L M Mir, D S Reintgen.   

Abstract

BACKGROUND: Electroporation is a process that causes a transient increase in the permeability of cell membranes. It can be used to increase the intracellular concentration of chemotherapeutic agents in tumor cells (electrochemotherapy; ECT). A clinical study was initiated to determine if this mode of treatment would be effective against certain primary and metastatic cutaneous malignancies. A group of six patients, three with malignant melanoma, two with basal cell carcinoma, and one with metastatic adenocarcinoma, were enrolled in the study. the treatment was administered in a two-step process.
METHODS: Each patient received a 10 unit/m2 dose of bleomycin administered intravenously at 1 to 1.5 units/minute. This was followed by eight 99 microsecond pulses at an amplitude of 1.3 kV/cm administered directly to the tumors 5 to 15 minutes after the bleomycin was completely infused. Pulses were administered after the injection of 1% lidocaine solution around the treatment site.
RESULTS: Two of three melanoma patients had objective responses. In these two patients, five of six treated tumors decreased in size, and three completely responded. Untreated tumors displayed continued growth. Objective responses were observed in both basal cell carcinoma (BCC) patients. One patient had partial responses in both treated tumors. The other patient had one of four primary BCCs respond completely, and the remaining three respond partially. Patients with metastatic breast adenocarcinoma showed complete responses in both treated nodules after ECT. All patients tolerated the treatment well with no residual effects from the electric pulses.
CONCLUSIONS: ECT was an effective local treatment in the majority of nodules treated. The results thus far are very encouraging and the study is being continued.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608491     DOI: 10.1002/(sici)1097-0142(19960301)77:5<964::aid-cncr24>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

1.  Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.

Authors:  Daniel E Spratt; Elizabeth A Gordon Spratt; Shenhong Wu; Antonio DeRosa; Nancy Y Lee; Mario E Lacouture; Christopher A Barker
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 2.  Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.

Authors:  Angela M Bodles-Brakhop; Richard Heller; Ruxandra Draghia-Akli
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

Review 3.  Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future.

Authors:  L M Mir
Journal:  Mol Biotechnol       Date:  2009-06-27       Impact factor: 2.695

Review 4.  Nanosecond electroporation: another look.

Authors:  Raji Sundararajan
Journal:  Mol Biotechnol       Date:  2008-09-26       Impact factor: 2.695

Review 5.  Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy.

Authors:  Vicente Muñoz Madero; Gloria Ortega Pérez
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

6.  Macromolecules as novel transdermal transport enhancers for skin electroporation.

Authors:  R Vanbever; M R Prausnitz; V Préat
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

Review 7.  Mechanisms of transfer of bioactive molecules through the cell membrane by electroporation.

Authors:  Mindaugas S Venslauskas; Saulius Šatkauskas
Journal:  Eur Biophys J       Date:  2015-05-05       Impact factor: 1.733

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 9.  Plasmid IL-12 electroporation in melanoma.

Authors:  Edward Cha; Adil Daud
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

10.  Electric pulses used in electrochemotherapy and electrogene therapy do not significantly change the expression profile of genes involved in the development of cancer in malignant melanoma cells.

Authors:  Vid Mlakar; Vesna Todorovic; Maja Cemazar; Damjan Glavac; Gregor Sersa
Journal:  BMC Cancer       Date:  2009-08-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.